{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:17:29Z","timestamp":1775153849842,"version":"3.50.1"},"reference-count":50,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is a lack of direct comparative studies evaluating the long\u2010term efficacy of the approved biologic therapies bimekizumab, secukinumab and adalimumab for moderate\u2010to\u2010severe hidradenitis suppurativa (HS) beyond Week 16. To address this evidence gap, this study uses matching\u2010adjusted indirect comparisons (MAIC) to assess and compare their sustained efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the long\u2010term relative efficacy of bimekizumab 320\u2009mg every 2\u2009weeks\/every 4\u2009weeks (Q2W\/Q4W) in moderate\u2010to\u2010severe HS compared with biologic therapies (secukinumab 300\u2009mg Q2W and Q4W and adalimumab 40\u2009mg every week [QW]) at Week 48\u201352.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Relevant trials were identified as part of a systematic literature review. Individual patient data for bimekizumab trials (BE HEARD I\/II; Week 48) were combined and subsequently weighted to match aggregate baseline characteristics of trials for secukinumab (SUNRISE\/SUNSHINE; Week 52) and adalimumab (PIONEER I\/II; Week 48). Weights for patients receiving bimekizumab were determined using a propensity score model. Unanchored comparisons of reweighted bimekizumab and comparator data for key HS efficacy outcomes were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Bimekizumab Q2W\/Q4W demonstrated significantly higher odds of response for all HS Clinical Response (HiSCR) and HS Severity Score System (IHS4) outcomes compared with secukinumab Q4W, including HiSCR50 (odds ratio [OR]: 2.68; 95% confidence interval [CI]: 1.71, 4.19), HiSCR75 (OR: 2.20; 95% CI: 1.48, 3.26) and IHS4\u201055 (OR: 2.27; 95% CI: 1.48, 3.48); and for HiSCR50\/75 compared with adalimumab QW (OR: 2.57; 95% CI: 1.48, 4.44\/OR: 1.84; 95% CI: 1.08, 3.13, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared with other approved biologics, bimekizumab showed favourable efficacy across the majority of outcomes assessed at Week 48\u201352, indicating its potential as a durable long\u2010term therapeutic option for patients with moderate\u2010to\u2010severe HS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70269","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:15:47Z","timestamp":1769595347000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long\u2010term efficacy of biologics in moderate\u2010to\u2010severe hidradenitis suppurativa: A systematic review and\n                    <scp>MAIC<\/scp>"],"prefix":"10.1111","author":[{"given":"Thrasyvoulos","family":"Tzellos","sequence":"first","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation, e.V.  Dessau Germany"},{"name":"Department of Dermatology Nordland Hospital Trust  Bod\u00f8 Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine Women's College Hospital  Toronto Ontario Canada"},{"name":"Division of Dermatology, Department of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Frank","family":"M\u00f8rup","sequence":"additional","affiliation":[{"name":"UCB  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Davis","sequence":"additional","affiliation":[{"name":"UCB  Morrisville North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Taieb","sequence":"additional","affiliation":[{"name":"UCB  Colombes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Kiri","sequence":"additional","affiliation":[{"name":"UCB  Slough UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Shodimu","sequence":"additional","affiliation":[{"name":"Source Health Economics  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abby","family":"Paine","sequence":"additional","affiliation":[{"name":"Source Health Economics  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[{"name":"St Vincent's University Hospital, Elm Park and the Charles Institute, University College Dublin  Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2760-3904","authenticated-orcid":false,"given":"Haley B.","family":"Naik","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of California  San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.1677"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16101"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/cimb45050280"},{"key":"e_1_2_14_6_1","unstructured":"BallardK ShumanVL.Hidradenitis suppurativa. StatPearls.2024."},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03356.x"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16132"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17166000"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17101"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16255"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e3181ceb80c"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.12703\/P6-112"},{"issue":"5","key":"e_1_2_14_14_1","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/bjd\/ljad215","article-title":"Healthcare experiences among patients with hidradenitis suppurativa: a qualitative study","volume":"189","author":"Sow Y","year":"2023","journal-title":"Br J Dermatol"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255560"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2021.1895753"},{"key":"e_1_2_14_17_1","unstructured":"National Institute for Health and Care Excellence (NICE).Adalimumab for treating moderate to severe hidradenitis suppurativa [ID812]. Committee papers. 2016. Available from:https:\/\/www.nice.org.uk\/guidance\/ta392\/documents\/committee\u2010papers(last accessed February 2025)."},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17578"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.016"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.068"},{"key":"e_1_2_14_21_1","unstructured":"European Medicines Agency (EMA).Cosentyx: EPAR \u2013 product information. Last updated 7 January 2025. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/cosentyx\u2010epar\u2010product\u2010information_en.pdf(last accessed February 2025)."},{"key":"e_1_2_14_22_1","unstructured":"European Medicines Agency (EMA).Humira EPAR \u2013 product information. Last updated 31 July 2024. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/humira\u2010epar\u2010product\u2010information_en.pdf(last accessed February 2025)."},{"key":"e_1_2_14_23_1","unstructured":"European Medicines Agency (EMA).Bimzelx EPAR \u2013 product information. Last updated 7 August 2024. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/bimzelx\u2010epar\u2010product\u2010information_en.pdf(last accessed February 2025)."},{"key":"e_1_2_14_24_1","unstructured":"U.S. Food and Drug Administration (FDA).Prescribing information HUMIRA (adalimumab). Revised: November 2023. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125057s423lbl.pdf(last accessed March 2025)."},{"key":"e_1_2_14_25_1","unstructured":"U.S. Food and Drug Administration (FDA).Prescribing information COSENTYX (secukinumab). Revised: August 2024. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125504s082lbl.pdf(last accessed March 2025)."},{"key":"e_1_2_14_26_1","unstructured":"U.S. Food and Drug Administration (FDA).Prescribing information BIMZELX (bimekizumab). Revised: October 2024. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761151s009lbl.pdf(last accessed March 2025)."},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118951651"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/096228020101000404"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X221097081"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.02.008"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70265"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_14_34_1","unstructured":"Centre for Reviews and Dissemination (CRD).Systematic Reviews. CRD's guidance for undertaking reviews in health care. 2009. Available from:https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf(last accessed August 2025)."},{"key":"e_1_2_14_35_1","unstructured":"Clinicaltrials.gov. A study to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (BE HEARD I). 2025. Available from:https:\/\/clinicaltrials.gov\/study\/NCT04242446(last accessed February 2025)."},{"key":"e_1_2_14_36_1","unstructured":"KimballAB ZouboulisCC SayedC KirbyJ PrensEP IngramJ et\u00a0al.Bimekizumab in patients with moderate\u2010to\u2010severe hidradenitis suppurativa: 48\u2010week efficacy and safety from BE HEARD I & II two phase 3 randomized double\u2010blind placebo controlled multicenter studies. American Academy of Dermatology Annual Meeting. 2023."},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00022-3"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.040"},{"key":"e_1_2_14_40_1","unstructured":"PhillippoD AdesT DiasS PalmerS AbramsKR WeltonN.NICE DSU technical support document 18: methods for population\u2010adjusted indirect comparisons in submissions to NICE.2016."},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13270"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18632"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15748"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1159\/000365390"},{"key":"e_1_2_14_45_1","unstructured":"van derHeijdeD GenslerL DeodharA BaraliakosX PoddubnyyD KivitzA et\u00a0al.Dual neutralization of IL\u201017A and IL\u201017F with bimekizumab in patients with active ankylosing spondylitis: 48\u2010week efficacy and safety results from a phase 2b randomized blinded placebo\u2010controlled dose\u2010ranging study. Abstract number 937. Presented at 2019 ACR\/ARP Annual Meeting. Available from:https:\/\/acrabstracts.org\/abstract\/dual\u2010neutralization\u2010of\u2010il\u201017a\u2010and\u2010il\u201017f\u2010with\u2010bimekizumab\u2010in\u2010patients\u2010with\u2010active\u2010ankylosing\u2010spondylitis\u201048\u2010week\u2010efficacy\u2010and\u2010safety\u2010results\u2010from\u2010a\u2010phase\u20102b\u2010randomized\u2010blinded\u2010placebo\u2010controlled\/(last accessed February 2025)."},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14075"},{"issue":"1","key":"e_1_2_14_47_1","article-title":"Quality\u2010of\u2010life impairment among patients with hidradenitis suppurativa: a cross\u2010sectional study of 1795 patients","volume":"11","author":"Krajewski PK","year":"2021","journal-title":"Life (Basel)"},{"key":"e_1_2_14_48_1","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/jamadermatol.2025.1976","article-title":"Efficacy and safety of medical interventions for moderate to severe hidradenitis suppurativa: a living systematic review and network meta\u2010analysis","volume":"161","author":"Garg A","year":"2025","journal-title":"JAMA Dermatol"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20617"},{"issue":"6","key":"e_1_2_14_50_1","article-title":"Biologics and small molecule inhibitors for treating hidradenitis suppurativa: a systematic review and meta\u2010analysis","volume":"10","author":"Huang CH","year":"2022","journal-title":"Biomedicine"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051351"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70269","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70269","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:15:50Z","timestamp":1769595350000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":50,"alternative-id":["10.1111\/jdv.70269"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70269","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"2025-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"jdv.70269"}}